German Diabetes Clinic Increases Diabetic Retinopathy Screenings From Zero to Thousands After Implementing Eyenuk’s EyeArt AI Eye Screening System
16.5.2019 10:05:00 EEST | Business Wire | Press release
Eyenuk Inc., a global artificial intelligence (AI) medical technology and services company and the leader in real-world applications for AI Eye Screening™, announced today results of its expansion into Germany. Since adopting the EyeArt AI Eye Screening System in October 2018, Diabetes Center Mergentheim has screened thousands of diabetic patients, identifying approximately 10% with cases of referable diabetic retinopathy (DR). The center is the first dedicated diabetic clinic in Germany to use artificial intelligence for screening of diabetic retinopathy, the leading cause of vision loss in working-age adults.1
The EyeArt AI Eye Screening System makes in-clinic, real-time DR screening possible for any physician, enabling quick and accurate identification of patients with referable DR during a diabetic patient’s regular physician visit. Once the patient’s fundus images have been captured and submitted to the EyeArt System, the DR screening results are available to view and export to a PDF report in less than 60 seconds. The EyeArt System can free eye care specialists to focus on sight-saving treatment rather than screening for DR.
At Diabetes Center Mergentheim, more than 20,000 patients with diabetes are seen each year by diabetes care specialists. Before adopting the EyeArt System, patients would be referred to ophthalmologists outside of the clinic. This process placed undue burden on patients, and often they would never get the necessary screening.
“EyeArt AI Eye Screening System is helping us improve diabetic patient care. We can now offer eye screening right in our clinic, without dilation, while reducing wait time for screening and results,” said Prof. Dr. med. Thomas Haak, head physician of Diabetes Center Mergentheim and founding member and board director of DiabetesDE. “The accuracy and convenience of the EyeArt System is allowing us to identify and treat DR effectively and quickly. The patients with no referable DR feel good that they can be screened again in a year, and the patients with identified referable DR can feel good that their silently progressing retinopathy has been identified and will be treated before any loss of sight.”
About 7.5 million people in Germany have diabetes mellitus2, with over 2,500 patients going blind due to diabetic retinopathy each year. German guidelines recommend at-risk patients be screened annually, but this can be difficult with the shortage of eye doctors. By incorporating the EyeArt System into their clinic, Diabetes Center Mergentheim has addressed a serious complication associated with diabetes — the center now screens 10 to 15 patients per day for this vision-threatening condition.
“Last year, we began our partnership with Diabetes Center Mergentheim with a great promise, and now it is very gratifying to see the promise turning into real meaningful impact that EyeArt System’s adoption is making to the diabetes patients in the Bad Mergentheim community,” said Kaushal Solanki, founder and CEO of Eyenuk. “We are now replicating our success to clinics throughout Germany, taking us one more step further in realizing our mission to screen every eye in the world.”
About Diabetic Retinopathy (DR)
DR is a complication of diabetes caused by damage to the blood vessels of the light-sensitive tissue at the back of the eye (retina). It is a silently progressing disease that at first may cause no symptoms or only mild vision problems. Eventually, it can cause blindness. The condition can develop in anyone who has type 1 or type 2 diabetes.3 It is estimated that one-third of all patients with diabetes will develop DR,4 making it the leading cause of vision loss in working-age adults.5
While DR screening is recommended for all diabetic patients, less than half get screened annually1, even in the developed world. Since diabetic patients outnumber ophthalmologists by 1,130 to 1 in Germany6, there are just not enough eye care specialists to meet the DR screening needs of the growing diabetic population. Even for those receiving an annual screening, ophthalmology appointment wait times for DR screening can be weeks or even months.
About the EyeArt AI Eye Screening System
The EyeArt AI Eye Screening System is the most extensively validated AI technology for autonomous detection of DR, tested in the real world on more than a half million patient visits globally with over 2 million images collected in real-world clinical environments. The EyeArt System was developed with funding from the U.S. National Institutes of Health (NIH) and is validated by the U.K. National Health Service (NHS). The EyeArt System has CE marking in the European Union and a Health Canada license. In the U.S., the EyeArt System is limited by federal law to investigational use.
About Eyenuk Inc.
Eyenuk Inc. is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening™ for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance. Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk and Alzheimer’s disease.
EyeArt is a registered trademark of Eyenuk Inc.
____________________
| 1 | Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Research. 2012;47:171-188. doi: 10.1159/000329603 | |
| 2 |
International Diabetes Federation (2017) IDF Diabetes Atlas, 8th edn. http://www.idf.org/diabetesatlas |
|
| 3 |
https://www.mayoclinic.org/diseases-conditions/diabetic-retinopathy/symptoms-causes/syc-20371611 |
|
| 4 | Yau JW, Rogers SL, Kawasaki R, et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes Care. 2012;35:556-64. doi: 10.2337/dc11-1909 | |
| 5 | Prokofyeva E, Zrenner E. Epidemiology of major eye diseases leading to blindness in Europe: a literature review. Ophthalmic Research. 2012;47:171-188. doi: 10.1159/000329603 | |
| 6 |
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190516005207/en/
Contact information
Media Contact:
Capwell Communications
Ida Yenney
ida@capwellcomm.com
949-999-3303
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ant International Research Highlights How Readable AI Memories Can Unlock More Personalised, Privacy-conscious Consumer Experiences2.11.2026 10:52:00 EET | Press release
Human sales and customer representatives have institutional memories to serve clients: their preferences and choices. How can we build a memory mechanism for AI services to create similarly personalised experiences? Ant International’s research on this subject recently received the Senior Area Chair (SAC) Highlight Award from the Best Paper Committee at EMNLP 2026, a leading global AI conference. Why do we need “readable AI memory”? In this paper titled 'Text as a universal interface for transferable personalisation', we look into one fact: until now, AI memory of a user has usually been generated and stored as dense numerical code only the original system can interpret. Two long-standing problems with that: First, today's user profiles are "black boxes" — opaque code locked inside a single app, so activity in one service teaches nothing to another, and every product has to re-learn you from scratch. Second, profiles are welded to the model that created them, so they don't transfer whe
Car Connectivity Consortium Expands Focus on Digital Access for Two-Wheelers and Micromobility2.11.2026 10:00:00 EET | Press release
The Car Connectivity Consortium® (CCC), the global organization advancing interoperable connectivity between vehicles and devices, today highlighted its expanding work across the two-wheeler and micromobility markets ahead of EICMA 2026 in Milan, Italy. Through its Light Motor & Mobility Task Group (LMTG), CCC is bringing member companies together to address the distinct digital access needs of these markets and identify opportunities to advance standardization and interoperability. Key highlights of CCC's two-wheeler and micromobility work include: Addressing two-wheeler digital access needs: LMTG is examining requirements across motorcycles, scooters, e-bikes and other two- and three-wheeled vehicles. Exploring new applications for digital key technology: Member discussions include vehicle access and starting, access to vehicle components, and digital key sharing. Building broader industry participation: CCC will engage with manufacturers and technology companies at EICMA 2026 to dis
Liberis and Qred Complete Merger Following Regulatory Approval to Create Global SMB Financial Platform2.11.2026 10:00:00 EET | Press release
Liberis, a leading global embedded finance platform, and Qred, one of Europe’s foremost digital small business banks, today announced the completion of their merger, first announced in June 2026, following approval from the Swedish Financial Supervisory Authority (SFSA). The merger combines Qred’s regulated banking capability and direct relationships with small businesses with Liberis’s embedded finance technology and distribution through more than 30 partners, including Deliveroo, Vagaro and Nexi. The group serves more than 60,000 small businesses across 17 countries and has access to approximately 11.5 million addressable merchants. Qred’s deposit-funded banking model and direct customer relationships complement Liberis’s partner-led distribution. Together, the businesses bring two routes to small business finance: through a regulated bank and through platforms that businesses already use. The group’s ambition is to broaden the financial services available to small businesses and its
OpenGate Capital Completes the Acquisition of Maersk Training, the Global Safety Training and Gas Safety Services Business of Maersk2.11.2026 10:00:00 EET | Press release
OpenGate Capital (“OpenGate”), a global private equity firm, announced today that it has completed the acquisition of Maersk Training and its subsidiary Maersk H2S Safety Services. The company, a provider of global safety training and gas safety services, is being carved out from A.P. Møller - Mærsk A/S (MAERSK A:CPH), a listed integrated logistics company. Terms of the acquisition were not disclosed. Headquartered in Svendborg, Denmark, Maersk Training is a leading global provider of essential safety services and training. Through Maersk H2S Safety Services, the company provides specialized outsourced hydrogen sulphide and Health, Safety and Environment safety services for customers in high-risk operating environments. The H2S Safety Services team provides onsite supervision, monitoring and safety equipment maintenance where the safety of personnel and the protection of assets are critical. Through its training business, the company also delivers safety training, competency developmen
Sofinnova Partners Promotes Javier Nunez-Vicandi to Partner, Strengthening Its Digital Medicine Strategy2.11.2026 09:00:00 EET | Press release
Sofinnova Partners ("Sofinnova"), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, today announced the promotion of Javier Nunez-Vicandi to Partner. He joins Edward Kliphuis and Simon Turner in the firm’s Digital Medicine strategy, which invests in startups working at the intersection of biology, data, and AI. Since joining Sofinnova in 2022, Nunez-Vicandi has played a key role in the development of the firm's Digital Medicine strategy and broader AI efforts. He helped shape key AI investment theses within the Digital Medicine Strategy and is an observer on the boards of Latent Labs, Bioptimus, Cure51, Deepc, and Kiro. Javier has also recently led an investment that remains in stealth. Within Sofinnova's broader AI efforts, Javier co-led the project that created Sofia, Sofinnova's proprietary AI platform, which supports investments and scientific analysis. As part of this effort, Javier helped lead the firm's collaborations with AWS and NVIDI
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom